Zofran
Company: GlaxoWellcome
Approval Status: Approved April 1998
Treatment for: postoperative vomiting and nausea in adults
Areas: Oncology
Possible similar drugs: Zofran ODT
| General Information | Side Effects |
General Information
An intramuscular administration of Zofran for postoperative nausea and vomiting in adults has been approved by the FDA. Normally, Zofran is given through an IV injection or in tablet form. This new intramuscular (IM) administration bypasses difficulties some patients may encounter. For example, some patients have difficulty swallowing, have small veins, or have veins that won't allow an IV to enter.
While IM administration has been approved in adults, it has not gained clearance for use in children.
Side Effects
Negative side effects have been noted in postoperative clinical tests The most common are dizziness, headache, drowsiness, sedation, and constipation. Other adverse effects are diarrhea, dry mouth, and skin rash.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
